Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's
- Conditions
- Crohn's Disease With Perianal Fistulas
- Interventions
- Registration Number
- NCT00736983
- Lead Sponsor
- Foundation for Liver Research
- Brief Summary
To assess whether a combination of ciprofloxacin and adalimumab is more effective than adalimumab alone for the treatment of perianal fistulas in Crohn's disease
- Detailed Description
Dutch multicenter, randomized, double-blind study with two arms. 146 patients will be included.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
- proven Crohn's disease
- Single or multiple draining perianal fistulas
- Abscesses
- Infliximab, cyclosporine, tacrolimus and antibiotics for Crohn's disease within past 3 months
- active viral infection
- significate cardiovascular dysfunction
- Pregnancy, Lactation
- Surgical bowel resection to be expected within 6 months
- Positive stool culture for enteric pathogens
- Total parental nutrition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 adalimumab Adalimumab 2 ciprofloxacin ciprofloxacin
- Primary Outcome Measures
Name Time Method Reduction of 50% or more from baseline to week 12 in the number of draining perianal fistulas. 12 week
- Secondary Outcome Measures
Name Time Method Proportion of patients in remission 12 week
Trial Locations
- Locations (13)
LUMC
🇳🇱Leiden, Netherlands
St Antonius ziekenhuis
🇳🇱Nieuwegein, Netherlands
UMC Radboud
🇳🇱Nijmegen, Netherlands
Medisch Spectrum Twente
🇳🇱Enschede, Netherlands
Haga ziekenhuis
🇳🇱Den Haag, Netherlands
AMC
🇳🇱Amsterdam, Netherlands
UMC Gronigen
🇳🇱Groningen, Netherlands
VU
🇳🇱Amsterdam, Netherlands
Deventer ziekenhuis
🇳🇱Deventer, Netherlands
UMC Utrecht
🇳🇱Utrecht, Netherlands
AZ Maastricht
🇳🇱Maastricht, Netherlands
Albert Schweitzer ziekenhuis
🇳🇱Dordrecht, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands